A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence

被引:95
作者
Ross, Susan [1 ]
Samuels, Ebony [2 ]
Gairy, Kerry [2 ]
Iqbal, Sheikh [3 ]
Badamgarav, Enkhe [3 ]
Siris, Ethel [4 ]
机构
[1] SD Ross Consulting, Cohasset, SD USA
[2] Heron Evidence Dev, London, England
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Columbia Univ, Med Ctr, New York, NY USA
关键词
adherence; compliance; fracture; meta-analysis; osteoporosis; POSTMENOPAUSAL OSTEOPOROSIS; DRUG-THERAPY; BISPHOSPHONATE THERAPY; NONVERTEBRAL FRACTURES; ORAL BISPHOSPHONATES; DATABASE ANALYSIS; CLINICAL-TRIAL; UNITED-STATES; HEALTH-CARE; ADHERENCE;
D O I
10.1016/j.jval.2010.11.010
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Therapy for osteoporosis reduces the risk of fracture in clinical trials; real-world adherence to therapy is suboptimal and may reduce the effectiveness of intervention. The objective was to assess the fracture risk among patients nonadherent versus adherent to therapy for osteoporosis. Methods: Medline, Embase, and CINAHL were searched for English-language publications of observational studies (January 1998-February 2009). Proceedings from two recent meetings of five relevant conferences were hand searched. Prospective and retrospective observational studies of patients with osteoporosis receiving bisphosphonates, parathyroid hormone, or selective estrogen receptor modulators denosumab were included. Studies were required to consider both fracture risk and adherence (compliance and/or persistence); any definition of adherence/fracture was acceptable. Data were analyzed using pooled comparisons of the odds and hazard ratios of fracture in noncompliance versus compliance and nonpersistence versus persistence. Sensitivity analyses were conducted to determine the effect of clinical heterogeneity on the results. Results: Twenty-seven citations were identified, the majority of which were retrospective database analyses considering the effect of adherence to bisphosphonate therapy on fracture at any skeletal site. The absolute frequency of fracture ranged from 6% to 38% with noncompliance and from 5% to 19% with nonpersistence (104-159 weeks). Meta-analysis indicates that fracture risk increases by approximately 30% with noncompliance (odds ratio [95% confidence interval] 1.29 [1.22-1.38]; hazard ratio 1.28 [1.18-1.38]) and by 30% to 40% with nonpersistence (odds ratio 1.40 [1.29-1.52]; hazard ratio 1.32 [1.23-1.42]). Conclusions: Poor medication adherence is associated with a significantly increased risk of fracture versus optimal adherence. Improving medication adherence in patients with osteoporosis may lead to a greater reduction in fracture.
引用
收藏
页码:571 / 581
页数:11
相关论文
共 54 条
  • [1] Osteoporosis treatment and fracture incidence: the ICARO longitudinal study
    Adami, S.
    Isaia, G.
    Luisetto, G.
    Minisola, S.
    Sinigaglia, L.
    Silvestri, S.
    Agnusdei, D.
    Gentilella, R.
    Nuti, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2008, 19 (08) : 1219 - 1223
  • [2] Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study
    Adami, Silvano
    Isaia, Giancarlo
    Luisetto, Giovanni
    Minisola, Salvatore
    Sinigaglia, Luigi
    Gentilella, Raffaella
    Agnusdei, Donato
    Iori, Nicoletta
    Nuti, Ranuccio
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (10) : 1565 - 1570
  • [3] [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
  • [4] A new look at osteoporosis outcomes: The influence of treatment, compliance, persistence, and adherence
    Badamgarav, Enkhe
    Fitzpatrick, Lorraine A.
    [J]. MAYO CLINIC PROCEEDINGS, 2006, 81 (08) : 1009 - 1012
  • [5] Loss of treatment benefit due to low compliance with bisphosphonate therapy
    Beest, F. J. A. Penning-van
    Erkens, J. A.
    Olson, M.
    Herings, R. M. C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) : 511 - 517
  • [6] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Black, Dennis M.
    Delmas, Pierre D.
    Eastell, Richard
    Reid, Ian R.
    Boonen, Steven
    Cauley, Jane A.
    Cosman, Felicia
    Lakatos, Peter
    Leung, Ping Chung
    Man, Zulema
    Mautalen, Carlos
    Mesenbrink, Peter
    Hu, Huilin
    Caminis, John
    Tong, Karen
    Rosario-Jansen, Theresa
    Krasnow, Joel
    Hue, Trisha F.
    Sellmeyer, Deborah
    Eriksen, Erik Fink
    Cummings, Steven R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) : 1809 - 1822
  • [7] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    Black, DM
    Cummings, SR
    Karpf, DB
    Cauley, JA
    Thompson, DE
    Nevitt, MC
    Bauer, DC
    Genant, HK
    Haskell, WL
    Marcus, R
    Ott, SM
    Torner, JC
    Quandt, SA
    Reiss, TF
    Ensrud, KE
    [J]. LANCET, 1996, 348 (9041) : 1535 - 1541
  • [8] Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women
    Blouin, Julie
    Dragomir, Alice
    Moride, Yola
    Ste-Marie, Louis-Georges
    Fernandes, Julio Cesar
    Perreault, Sylvie
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (01) : 117 - 127
  • [9] Consequences of poor compliance with bisphosphonates
    Briesacher, Becky A.
    Andrade, Susan E.
    Yood, Robert A.
    Kahler, Kristijan H.
    [J]. BONE, 2007, 41 (05) : 882 - 887
  • [10] Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]